Does gallbladder risk persist once weight has stabilised?

I have kept a symptom diary against dose dates, which turns out to have been the useful thing.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

What is the causal chain, and where does it stop being established?

The relevant physiology is that mobilised cholesterol is excreted in bile while gallbladder contractility falls with reduced fat intake — a supersaturated bile that is not being emptied.

The historical figure from very-low-energy diet studies is that gallstones form in a substantial minority — often quoted between ten and twenty-five per cent — during rapid loss, with a much smaller fraction becoming symptomatic.

On the detail: ursodeoxycholic acid has evidence for reducing stone formation during rapid weight loss and is a prescribing decision rather than a supplement choice.

Research-use compounds are not approved for human use.

Recognise biliary colic: right upper quadrant, after fatty food, thirty minutes to hours.

Answering this needs to know the rate and whether there is a history of stones, since prior stones change the picture materially.

Fever, jaundice or persistent pain beyond a few hours suggests complication rather than simple colic and is urgent.

Concretely, two mechanisms operate together during rapid loss: cholesterol mobilised from adipose tissue is excreted into bile, raising its cholesterol saturation index; and reduced fat intake reduces cholecystokinin release, so the gallbladder contracts less often.

Fever or jaundice with pain is urgent. Do not wait.

Mechanically, this is one of the few adverse outcomes in this class with a clean mechanistic explanation and a clear modifiable factor.

The trial programmes in this class report cholelithiasis at low single-figure percentages, higher than placebo, consistent with the weight-loss mechanism rather than a novel one.

The caveat is that severe abdominal pain with fever or jaundice is an emergency and not a topic for discussion.

This is a weight-loss risk with a known mechanism, not a mysterious drug effect.

The short version: rapid loss raises biliary cholesterol saturation and reduces gallbladder emptying, and both push towards stone formation.

Loss rates above about 1.5 kilograms a week are where the risk climbs most steeply in the older literature, which is a practical argument against the fastest possible trajectory.

Trial programmes in this class report cholelithiasis as an adverse event at rates above placebo and consistent with the magnitude of weight loss achieved.

Rate of loss is the modifiable factor. Slower is genuinely safer here.

edited 14 Jun 2025 by Dr_Bram_Verhoeven — added the placebo-arm figures